Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-β

[1]  P. Dagnelie,et al.  Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study , 2021, Diabetologia.

[2]  Joanne S. Robertson,et al.  Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease , 2021, Journal of Alzheimer's disease reports.

[3]  Alessandro Didonna.  Tau at the interface between neurodegeneration and neuroinflammation , 2020, Genes & Immunity.

[4]  M. Delorenzi,et al.  Systemic and central nervous system metabolic alterations in Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[5]  K. Blennow,et al.  Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease , 2019, Journal of Neuroinflammation.

[6]  Henrik Zetterberg,et al.  Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer's disease and relationship to amyloid-β and tau , 2019, Neurobiology of Aging.

[7]  Yujin Guo,et al.  Curcumin relieves depressive-like behaviors via inhibition of the NLRP3 inflammasome and kynurenine pathway in rats suffering from chronic unpredictable mild stress. , 2019, International immunopharmacology.

[8]  C. Lim,et al.  Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms , 2019, Neurotoxicity Research.

[9]  D. Aarsland,et al.  The Associations Between Cognitive Prognosis and Kynurenines Are Modified by the Apolipoprotein ε4 Allele Variant in Patients With Dementia , 2019, International journal of tryptophan research : IJTR.

[10]  Olivier Salvado,et al.  Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL , 2018, NeuroImage.

[11]  Liuqing Di,et al.  Suppressive Effect of Ginsenoside Rg3 against Lipopolysaccharide-Induced Depression-Like Behavior and Neuroinflammation in Mice. , 2017, Journal of agricultural and food chemistry.

[12]  R. Kozak,et al.  Kynurenine pathway in schizophrenia: Galantamine-memantine combination for cognitive impairments , 2017, Schizophrenia Research.

[13]  G. Guillemin,et al.  Major Developments in the Design of Inhibitors along the Kynurenine Pathway , 2017, Current medicinal chemistry.

[14]  Bruce V. Taylor,et al.  Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression , 2017, Scientific Reports.

[15]  H. Bae,et al.  Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model , 2016, Oncotarget.

[16]  E. Hol,et al.  Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease , 2016, Progress in Neurobiology.

[17]  R. Nitsch,et al.  T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer’s disease-like cerebral amyloidosis , 2016, Brain, Behavior, and Immunity.

[18]  Juliet M. Taylor,et al.  The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease , 2016, Journal of neurochemistry.

[19]  M. Schwartz,et al.  Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer's disease pathology , 2015, Nature Communications.

[20]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[21]  R. Sperling,et al.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. , 2014, JAMA neurology.

[22]  W. Lee,et al.  The tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation. , 2013, International immunopharmacology.

[23]  H. Hampel,et al.  Increased 3-Hydroxykynurenine serum concentrations differentiate Alzheimer’s disease patients from controls , 2013, European Archives of Psychiatry and Clinical Neuroscience.

[24]  Gilles J. Guillemin,et al.  Expression of Tryptophan 2,3-Dioxygenase and Production of Kynurenine Pathway Metabolites in Triple Transgenic Mice and Human Alzheimer's Disease Brain , 2013, PloS one.

[25]  G. Guillemin.  Quinolinic acid, the inescapable neurotoxin , 2012, The FEBS journal.

[26]  Sunhee C. Lee,et al.  The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. , 2011, The American journal of pathology.

[27]  R. Schwarcz,et al.  Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration , 2011, Cell.

[28]  C. Rowe,et al.  Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.

[29]  Nicholas Stoy,et al.  On the Biological Importance of the 3-hydroxyanthranilic Acid: Anthranilic Acid Ratio , 2010, International journal of tryptophan research : IJTR.

[30]  Gilles J. Guillemin,et al.  The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons , 2009, PloS one.

[31]  B. Brew,et al.  Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and Neurons , 2009, Neurotoxicity Research.

[32]  Gilles J Guillemin,et al.  Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.

[33]  Gregory I. Elliott,et al.  3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis , 2007, Proceedings of the National Academy of Sciences.

[34]  János Kálmán,et al.  Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease , 2007, Neurochemistry International.

[35]  D. Fuchs,et al.  Resveratrol suppresses interferon-gamma-induced biochemical pathways in human peripheral blood mononuclear cells in vitro. , 2005, Immunology letters.

[36]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.

[37]  T. Stone,et al.  Tryptophan metabolism and oxidative stress in patients with Huntington's disease , 2005, Journal of neurochemistry.

[38]  Byung-Min Choi,et al.  3-Hydroxyanthranilic acid, one of metabolites of tryptophan via indoleamine 2,3-dioxygenase pathway, suppresses inducible nitric oxide synthase expression by enhancing heme oxygenase-1 expression. , 2004, Biochemical and biophysical research communications.

[39]  Masanori Kato,et al.  Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases , 2002, Journal of Neuroimmunology.

[40]  L. Chylack,et al.  3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. , 2000, Biochemistry.

[41]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[42]  N. Nishiyama,et al.  3‐Hydroxykynurenine, an Endogenous Oxidative Stress Generator, Causes Neuronal Cell Death with Apoptotic Features and Region Selectivity , 1998, Journal of neurochemistry.

[43]  Per Magne Ueland,et al.  Kynurenine Pathway Metabolites in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[44]  Reisa A. Sperling,et al.  Alzheimer's disease , 2015, Nature Reviews Disease Primers.

[45]  D. Pawlak,et al.  Kynurenine and its metabolites in Alzheimer's disease patients. , 2010, Advances in medical sciences.

[46]  J C Adair,et al.  Is it Alzheimer's? , 1998, Hospital practice.